Attruby (acoramidis) — Medica

Cardiomyopathy of wild-type or hereditary (variant) transthyretin-mediated amyloidosis (ATTR-CM)

Initial criteria

age ≥ 18 years
Diagnosis confirmed by ONE of the following: (i) technetium pyrophosphate scan (nuclear scintigraphy); OR (ii) tissue biopsy with confirmatory transthyretin (TTR) amyloid typing by mass spectrometry, immunoelectron microscopy, or immunohistochemistry; OR (iii) genetic testing identifying a TTR pathogenic variant
Diagnostic cardiac imaging has demonstrated cardiac involvement (e.g., echocardiogram or cardiac magnetic imaging showing increased thickness of the ventricular wall or interventricular septum)
Patient has heart failure but does not have New York Heart Association class IV disease
Medication is prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis
NOT used concurrently with other medications indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy (e.g., Amvuttra [vutrisiran], Onpattro [patisiran], Tegsedi [inotersen], Wainua [eplontersen], tafamidis products)

1 year